Background The clinical efficacy and safety of SGLT2i in treating patients with type 2
diabetes mellitus and hypertension lack immense data support. Objective To systematically …

Objectives Heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with
preserved ejection fraction (HFpEF) are associated with significant morbidity and mortality …

Sodium–glucose transport inhibitors (SGLT2i) are effective in heart failure (HF) with ejection
fraction (EF)< 40%(referred to as HF with reduced EF–HFrEF) and left ventricular EF …

Introduction Sodium glucose cotransporter-2 inhibitors (SGLT2is) are an emerging class of
drugs with wide indications. Controversial evidence exists regarding the risk of urinary tract …

Introduction Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic
agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug–drug …

Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are novel agents for
heart failure (HF) and are now recommended in guidelines. Understanding general …

Abstract Sodium-glucose cotransoporter-2 inhibitors (SGLT-2Is) improve prognosis in heart
failure (HF) patients both with reduced ejection fraction (HFrEF) and preserved ejection …

Background: Several studies have shown that sodium-dependent glucose transporter 2
inhibitors can be used in the treatment of heart failure. This article summarized systematic …

Background The effectiveness and safety of a novel class of hypoglycemic medications
known as sodium-glucose cotransporter 2 (SGLT2) inhibitors have not been completely …

The aim of this study was to investigate the effects of SGLT2 inhibitors (SGLT2i) on patients
with heart failure (HF) and reduced ejection fraction, with or without diabetes. A systematic …